FDA Brief

Warning letters Drugs

FDA warning letter to

Gulsah Uretim Kozmetik Sanayi Anonim Sirketi

High riskIssued May 13, 2021Posted Aug 31, 2021Center for Drug Evaluation and Research | CDER

Turkish OTC drug maker Gulsah failed to test its products and ingredients, and FDA blocked its U.S. imports.

What happened

FDA did not inspect the plant; instead it asked Gulsah for records on April 23, 2020 under section 704(a)(4) of the FD&C Act, which lets FDA demand records in place of an inspection. Follow-up teleconferences on July 16, 2020 and January 19, 2021 confirmed that the firm released batches shipped to the United States without testing identity and strength of the active ingredient, relied only on supplier certificates of analysis for incoming ingredient identity, and ran stability studies that did not test the active ingredient. FDA placed all of the firm's drug products on Import Alert 66-40 on March 29, 2021.

What FDA found

  1. The firm released batches without laboratory testing to confirm each batch met its specifications, including the identity and strength of the active ingredient.

    21 CFR 211.165(a)
  2. The firm did not test each incoming lot of active ingredient to confirm its identity, and did not validate that its supplier's test results were reliable.

    21 CFR 211.84(d)(1) and (2)
  3. The firm's stability studies did not test the active ingredient or degradation products, so they could not show the drug stays within specification through its expiration date.

    21 CFR 211.166(a)
  4. The firm's overall quality system was inadequate to meet CGMP requirements.

    21 CFR parts 210 and 211

What FDA wants

FDA tells the firm to correct the violations promptly and to reply in writing within 15 working days with a plan covering testing of reserve samples, supplier qualification, stability program fixes, and an independent review of its laboratory and materials systems. FDA also strongly recommends hiring a qualified CGMP consultant to audit the whole operation.

Who should pay attention

  • U.S. brands and distributors that buy OTC finished product from this contract manufacturer
  • companies sourcing over-the-counter drugs made in Turkey
  • quality teams that rely on supplier certificates of analysis instead of identity testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk